Barr Laboratories on Wednesday announced that the FDA has granted final marketing approval to its generic version of Kytril, Roche Laboratories' drug for preventing nausea and vomiting associated with cancer therapy.
Published in Brief:
|Legal & Regulatory Analysis Specialist||
Health Care Service Corporation
|Call Center Leader||
Bluegrass Family Health
Gilead Science Inc
|Foster City, CA|